Immune monitoring of SARS-CoV-2-specific T cell and B cell responses in patients with multiple sclerosis treated with ocrelizumab.

Front Immunol · 2023 · PMC10569464 · PMID 37841269

Europe PMC DOI

hedged sentence

0.0515

closest p · 1.0× alpha

0.0515

boldest claim

The sentences

a decreasing trendP = 0.0515so close (0.05 < p ≤ 0.1)

Interestingly, the reduction in the B cell response was restricted mostly to the spike S1 + S2 proteins ( P = 0.0012), while for the NC protein only a decreasing trend was observed ( P = 0.0515) ( Figure 2B ).

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.